Overview
James Cohen, Jiayan Chen, and Michael Ryan wrote this bylined article describing new FDA rules governing how manufacturers disseminate new risk information relating to approved uses of a prescription drug. “In light of the variability in evidence and the potential for new risk information to generate confusion among providers, … the FDA found that guidance was necessary to help ensure the appropriate distribution of such information,” the authors wrote, adding that it brings “some welcome clarity” despite its limitations.